5 Undervalued Biotechnology & Medical Research Stocks for Friday, February 09
Discover the top 5 undervalued Biotechnology & Medical Research stocks for Friday, February 09 based on AAII’s Stock Grades.Jack Gilleland
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
GlucoTrack, Inc., a medical device company, focuses on the development of an implantable continuous blood glucose monitor (CBGM) for people with diabetes in the United States. The company develops the GlucoTrack CBGM, a long-term implantable blood-based CBGM for use by Type 1 diabetes patients and insulin-dependent Type 2 diabetes patients. The company was formerly known as Integrity Applications, Inc. and changed its name to GlucoTrack, Inc. in November 2021. GlucoTrack, Inc. was founded in 2001 and is based in Rutherford, New Jersey.
Commentary & Analysis
7 Undervalued Biotechnology & Medical Research Stocks for Wednesday, January 10
Discover the top 7 undervalued Biotechnology & Medical Research stocks for Wednesday, January 10 based on AAII’s Stock Grades.Eunice Kim
3 Undervalued Advanced Medical Equipment & Technology Stocks for Wednesday, November 08
Discover the top 3 undervalued Advanced Medical Equipment & Technology stocks for Wednesday, November 08 based on AAII’s Stock Grades.Grace Malone
3 Undervalued Advanced Medical Equipment & Technology Stocks for Tuesday, September 26
Discover the top 3 undervalued Advanced Medical Equipment & Technology stocks for Tuesday, September 26 based on AAII’s Stock Grades.Eunice Kim
4 Undervalued Advanced Medical Equipment & Technology Stocks for Thursday, August 24
Discover the top 4 undervalued Advanced Medical Equipment & Technology stocks for Thursday, August 24 based on AAII’s Stock Grades.Grace Malone
Financial Summary
| Share Statistics | GCTK | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $1.9 | $366.1 | 1% |
|
| Shares Out (Mil) | 0.3 | 40.8 | 2% |
|
| Institutional Ownership | 99.4% | 83.3% | 87% |
|
| Float (Mil) | 0.8 | 35.1 | 2% |
|
| Beta | na | 0.87 | na |
|
| Avg Daily Volume (000s) | 127 | 299 | 39% |
|
| Price Change (52-week) |
(98.0%) | 63.3% | 2% |
|
| Growth | GCTK | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | na | 11.8% | na |
|
| Net Income (5yr) | (48.4%) | (5.7%) | 7% |
|
| EPS (5yr) | na | 10.2% | na |
|
| Dividends (5yr) | na | 0.0% | na |
|
| Cash Flow (5yr) | na | (15.5%) | na |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | na | na | na | |
| Current EPS | na | na | na | |
| Month Ago EPS | na | na | na | |
| # Rev Up | na | na | na | |
| # Rev Down | na | na | na | |
| Three Months Ago EPS | na | na | na | |
| Year/Year Chg | na | na | na | |
| Financials | GCTK | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | na | $119 | na |
|
| Net Income (TTM) (Mil) | ($16) | ($9) | 26% |
|
| EPS (TTM) | ($112.775) | ($0.400) | 1% |
|
| Operating Cash Flow (TTM) (Mil) | ($16) | ($3) | 16% |
|
| Net Cash Flow (TTM) (Mil) | na | $1 | na |
|
| Long-Term Debt (Q1) (Mil) | $0 | $23 | 12% |
|
| Enterprise Value (Q1) (Mil) | $3 | $376 | 4% |
|
| Valuation | GCTK | Industry Median |
Percentile (All Stocks) |
|
| P/B | na | 2.80 | na |
|
| P/E | na | 25.7 | na |
|
| Dividend Yield | na | 0.0% | na |
|
| PEG (5yr hist) | na | 1.4 | na |
|
| Ratios | GCTK | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | na | 58.5% | na |
|
| Net Margin | na | (6.9%) | na |
|
| ROA | (272.5%) | (12.3%) | 1% |
|
| ROE | (620.6%) | (11.1%) | 1% |
|
| Liabilities to Assets | 216.5% | 46.6% | 99% |
|
| F-Score | 2 | 4 | na |
|
GlucoTrack, Inc. did not pass any screens on 9/17/2026.
